Loading...
ROCO
4128
Market cap389mUSD
Nov 12, Last price  
20.70TWD
Name

Microbio Co Ltd

Chart & Performance

D1W1MN
ROCO:4128 chart
P/E
—
P/S
7.07
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.56%
Rev. gr., 5y
3.28%
Revenues
1.72b
+8.26%
231,532,000155,603,000512,593,000737,671,0001,079,118,0001,194,787,0001,177,656,0001,167,834,0001,399,356,0001,518,853,0001,522,436,0001,412,791,0001,448,533,0001,466,308,0001,601,399,0001,782,038,0001,721,848,0001,591,392,0001,722,852,000
Net income
-1.10b
L-6.70%
-24,087,000-123,426,00025,940,000-81,767,000412,532,000280,368,000-33,290,000-129,116,000-140,426,000-193,692,000-267,815,000543,030,000-690,743,000-264,596,000519,839,000-233,160,000152,424,000-1,179,876,000-1,100,803,000
CFO
530m
P
4,388,000-95,298,000-143,212,000-485,097,000520,412,000-271,949,000-132,360,000-176,632,000-167,037,000-161,895,000-180,247,000-9,830,00015,849,00072,359,000109,817,00053,981,000141,566,000-118,754,000529,901,000
Dividend
Jun 16, 20230.0401 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630 to treat non-alcoholic steatohepatitis; FB918 for the treatment of non-allergic eosinophilic asthma; and SNS812 for Cov-flu. The company's Phase I clinical trial products consist of OB-318, an anti-cancer drug; MB-110 for the treatment of hepatitis C; SNP-810, an acetaminophen; FB317 to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria; and FB704A for the treatment of rheumatoid arthritis, cancer, cytokine storms, etc. It also offers FB825, which is in Phase II clinical trial for the treatment of atopic dermatitis, allergic asthma, hyper IgE syndrome, and food allergy. In addition, the company's Phase III clinical trial products comprise ON101 to treat diabetic foot ulcer; and MB-6 that acts as an adjuvant for metastatic colorectal cancer. Further, its discovery stage pipeline includes FB121 for AIDS; SNA01 to treat PD-1 related cancer; SNA02 for cancer immune therapy; and SNS01 for recurrent metastatic non-small cell lung cancer. Additionally, the company develops SNP-830 and SNP-840, a hepatotoxicity-free analgesic. It is also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was founded in 2000 and is based in Taipei, Taiwan.
URL
https://www.microbio.com.tw/
IPO date
Feb 10, 2003
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT